Epidemias y pandemias, una aproximación histórica / Epidemics and pandemics, a historical approach

Resumen Se presenta una aproximación histórica a los momentos más importantes de las epidemias y las pandemias, toda vez que se trata de un tema muy vigente en la actualidad por cuenta de la situación sanitaria que nos está afectando. Se analizan las influencias religiosas, políticas, económicas y sociales que modificaron en gran parte el desarrollo y el resultado final de las epidemias en las diferentes épocas de la humanidad. Este repaso por la historia de las epidemias y las pandemias nos muestra que enfermedades como la viruela y el sarampión fueron muy importantes en la antigüedad, que la peste y el tifus reclamaron preponderancia durante la Edad Media, y que en el siglo XX la influenza (en sus diferentes manifestaciones: gripa española, gripe aviar y gripe porcina) y el cólera, se posicionaron como los azotes principales, convirtiéndose todas ellas en grandes hitos en la historia de la medicina. Se muestra la importancia de la microbiología, la epidemiología y la salud pública en el entendimiento y enfoque adecuado de las infecciones. Por último, se ofrecen algunas reflexiones sobre la lucha de imaginarios entre la ciencia y la creencia. (Acta Med Colomb 2021; 46. DOI: https://doi.org/10.36104/amc.2021.2247).

Abstract This is a historical approach to the most important epidemic and pandemic moments, a very relevant topic today given our current healthcare situation. The religious, political, economic and social influences which largely modified the development and final outcome of epidemics throughout human history are analyzed. This review of the history of epidemics and pandemics shows us that diseases like smallpox and measles were very important in ancient times, that the plague and typhus regained prevalence during the Middle Ages, and that influenza (in its various forms: Spanish flu, avian flu, and swine flu) and cholera positioned themselves as the main scourges of the twentieth century, all of them becoming major milestones in the history of medicine. This article shows the importance of microbiology, epidemiology and public health in understanding and having a proper approach to infections. Finally, the author offers a few concluding thoughts on the struggle between the imaginaries of science and belief. (Acta Med Colomb 2021; 46. DOI: https://doi.org/10.36104/amc.2021.2247).

The prediction of Metabolic Syndrome alterations is improved by combining waist circumference and handgrip strength measurements compared to either alone.

BACKGROUND: Adiposity is a major component of the metabolic syndrome (MetS), low muscle strength has also been identified as a risk factor for MetS and for cardiovascular disease. We describe the prevalence of MetS and evaluate the relationship between muscle strength, anthropometric measures of adiposity, and associations with the cluster of the components of MetS, in a middle-income country. METHODS: MetS was defined by the International Diabetes Federation criteria. To assess the association between anthropometric variables (waist circumference (WC), waist-to-hip ratio (W/H), body mass index (BMI)), strength (handgrip/kg bodyweight (HGS/BW)) and the cluster of MetS, we created a MetS score. For each alteration (high triglycerides, low HDLc, dysglycemia, or high blood pressure) one point was conferred. To evaluate the association an index of fat:muscle and MetS score, participants were divided into 9 groups based on combinations of sex-specific tertiles of WC and HGS/BW. RESULTS: The overall prevalence of MetS in the 5,026 participants (64% women; mean age 51.2 years) was 42%. Lower HGS/BW, and higher WC, BMI, and W/H were associated with a higher MetS score. Amongst the 9 HGS/BW:WC groups, participants in the lowest tertile of HGS/BW and the highest tertile of WC had a higher MetS score (OR = 4.69 in women and OR = 8.25 in men;p < 0.01) compared to those in the highest tertile of HGS/BW and in the lowest tertile of WC. CONCLUSION: WC was the principal risk factor for a high MetS score and an inverse association between HGS/BW and MetS score was found. Combining these anthropometric measures improved the prediction of metabolic alterations over either alone.

May Measurement Month 2018: an analysis of blood pressure screening results from Colombia.

High blood pressure (BP) is the leading global preventable cause of death and the most common risk factor for cardiovascular disease (CVD). However, due to its asymptomatic nature, the lack of awareness of this condition causes underdiagnosis and low rates of adherence to pharmacological treatment. Looking for practical approaches to increase awareness worldwide, the International Society of Hypertension (ISH) implemented the 2nd May Measurement Month campaign in 2018 (MMM18). In order to contribute to this initiative, Colombia participated as one of the 89 countries involved in this hypertension screening programme. Blood pressure was measured in subjects from 11 departments in Colombia. Under the leadership of the Fundación Oftalmológica de Santander (FOSCAL), 400 volunteers across the country collected the data following the MMM protocol. Measurements from 35 548 participants with a mean age of 41.9 years were obtained. In total, 9475 (26.7%) of the total population studied had hypertension. Of those with hypertension, 69.9% of these subjects were aware of their condition, 65.0% were on antihypertensive medication, and 43.1% had controlled BP. Of those on medication, 66.3% had controlled BP. Hypertension screening, awareness, treatment, and control should be a priority in public health objectives due to its elevated burden of disease and direct association with increased CVD. The MMM campaign provided a positive impact in the diagnosis of hypertension across Colombia. Although efforts are being made to expand treatment capability and adherence, still more are needed to insure a broader coverage of antihypertensive medication in Colombia.

Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease.

BACKGROUND: Previous trials have shown that the use of statins to lower cholesterol reduces the risk of cardiovascular events among persons without cardiovascular disease. Those trials have involved persons with elevated lipid levels or inflammatory markers and involved mainly white persons. It is unclear whether the benefits of statins can be extended to an intermediate-risk, ethnically diverse population without cardiovascular disease. METHODS: In one comparison from a 2-by-2 factorial trial, we randomly assigned 12,705 participants in 21 countries who did not have cardiovascular disease and were at intermediate risk to receive rosuvastatin at a dose of 10 mg per day or placebo. The first coprimary outcome was the composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, and the second coprimary outcome additionally included revascularization, heart failure, and resuscitated cardiac arrest. The median follow-up was 5.6 years. RESULTS: The overall mean low-density lipoprotein cholesterol level was 26.5% lower in the rosuvastatin group than in the placebo group. The first coprimary outcome occurred in 235 participants (3.7%) in the rosuvastatin group and in 304 participants (4.8%) in the placebo group (hazard ratio, 0.76; 95% confidence interval [CI], 0.64 to 0.91; P=0.002). The results for the second coprimary outcome were consistent with the results for the first (occurring in 277 participants [4.4%] in the rosuvastatin group and in 363 participants [5.7%] in the placebo group; hazard ratio, 0.75; 95% CI, 0.64 to 0.88; P<0.001). The results were also consistent in subgroups defined according to cardiovascular risk at baseline, lipid level, C-reactive protein level, blood pressure, and race or ethnic group. In the rosuvastatin group, there was no excess of diabetes or cancers, but there was an excess of cataract surgery (in 3.8% of the participants, vs. 3.1% in the placebo group; P=0.02) and muscle symptoms (in 5.8% of the participants, vs. 4.7% in the placebo group; P=0.005). CONCLUSIONS: Treatment with rosuvastatin at a dose of 10 mg per day resulted in a significantly lower risk of cardiovascular events than placebo in an intermediate-risk, ethnically diverse population without cardiovascular disease. (Funded by the Canadian Institutes of Health Research and AstraZeneca; HOPE-3 ClinicalTrials.gov number, NCT00468923.).

Hiperglucemia se asocia a mayor número de desenlaces adversos en individuos latinoamericanos con infarto agudo de miocardio / Hyperglycaemia is associated with worse outcomes in Latin-American individuals with acute myocardial infarction

Introducción: Las alteraciones en el metabolismo de la glucosa son un factor de riesgo y de peor pronóstico para infarto agudo de miocardio (IAM), pero esta información en población latinoamericana es limitada. Por tanto, evaluamos la asociación del estado glucémico con desenlaces a corto y largo plazo en pacientes con un primer IAM. Métodos: Estudio observacional de cohorte, multicéntrico, prospectivo, conducido en 8 hospitales de Colombia y Ecuador. Resultados: Se incluyeron en total 439 pacientes con diagnóstico confirmado de IAM, de los cuales 305 (69,5%) presentaron prediabetes o diabetes mellitus tipo 2 (DM2). En comparación con el grupo de normoglucemia, los pacientes con DM2 conocida presentaron mayor riesgo de estancia hospitalaria prolongada (HR: 2,60, IC 95%: 1,38-4,92, p = 0,003), de Killip clase iii/iv (HR: 9,46, IC 95%: 2,20-40,62, p = 0,002) y de insuficiencia cardiaca intrahospitalaria (HR: 10,76, IC 95%: 3,37-34,31, p < 0,001). Los pacientes con prediabetes, DM2 conocida y DM2 nueva tuvieron tasas más altas de episodios adversos cardiovasculares mayores en el seguimiento a 3 años. Conclusión: Alteraciones en el metabolismo de la glucosa tienen una importante significación pronóstica a corto y a largo plazo en pacientes latinoamericanos sobrevivientes a un primer IAM

Background: Alterations in glucose metabolism have been reported as risk and poor prognostic factors for acute myocardial infarction (AMI); however in Latin-American population this information is limited. Thus, an evaluation was performed on the association between glycaemic status and short- and long-term outcomes in patients with a first AMI. Methods: A multicentre, prospective, observational, cohort study was conducted in 8 hospitals from Colombia and Ecuador. Results: A total of 439 patients with confirmed AMI were included, of which 305 (69.5%) had prediabetes or type 2 diabetes mellitus (DM2). Compared with normal glycaemia group, patients with known DM2 had greater risk of prolonged hospital stay (HR: 2.60, 95% CI: 1.38-4.92, P = .003), Killip class iii/iv (HR: 9.46, 95% CI: 2.20-40.62, P = .002), and in-hospital heart failure (HR: 10.76, 95% CI: 3.37-34.31, P < .001). Patients with prediabetes, new DM2, and known DM2 showed higher rates of major adverse cardiovascular events after 3 years follow-up. Conclusion: Glucose metabolism abnormalities have an important significance in the short- and long-term prognosis in Latin-American patients that survive a first AMI

[Hyperglycaemia is associated with worse outcomes in Latin-American individuals with acute myocardial infarction]. / Hiperglucemia se asocia a mayor número de desenlaces adversos en individuos latinoamericanos con infarto agudo de miocardio.

BACKGROUND: Alterations in glucose metabolism have been reported as risk and poor prognostic factors for acute myocardial infarction (AMI); however in Latin-American population this information is limited. Thus, an evaluation was performed on the association between glycaemic status and short- and long-term outcomes in patients with a first AMI. METHODS: A multicentre, prospective, observational, cohort study was conducted in 8 hospitals from Colombia and Ecuador. RESULTS: A total of 439 patients with confirmed AMI were included, of which 305 (69.5%) had prediabetes or type2 diabetes mellitus (DM2). Compared with normal glycaemia group, patients with known DM2 had greater risk of prolonged hospital stay (HR: 2.60, 95%CI: 1.38-4.92, P=.003), Killip class iii/iv (HR: 9.46, 95%CI: 2.20-40.62, P=.002), and in-hospital heart failure (HR: 10.76, 95%CI: 3.37-34.31, P<.001). Patients with prediabetes, new DM2, and known DM2 showed higher rates of major adverse cardiovascular events after 3years follow-up. CONCLUSION: Glucose metabolism abnormalities have an important significance in the short- and long-term prognosis in Latin-American patients that survive a first AMI.

Guía de práctica clínica para la prevención, detección temprana, diagnóstico, tratamiento y seguimiento de las dislipidemias: tratamiento farmacológico con estatinas / Clinical practice guidelines for prevention, early detection, diagnose, treatment and follow-up of dyslipidemias: farmacological treatment with statins

Objetivo: Evaluar el impacto del tratamiento con estatinas sobre la incidencia y la recurrencia de los eventos cardiovasculares y los cerebrovasculares (prevención primaria y secundaria), los niveles de las fracciones lipídicas y la incidencia de efectos secundarios (el cáncer y la diabetes mellitus) en personas con hipercolesterolemia. Métodos: Se elaboró una guía de práctica clínica siguiendo los lineamientos de la guía metodológica del Ministerio de Salud y Protección Social para recolectar de forma sistemática la evidencia científica y formular las recomendaciones utilizando la metodología GRADE. Resultados: Se evidenció un efecto benéfico del tratamiento farmacológico con estatinas tanto en población de prevención primaria como en prevención secundaria, logrando reducciones clínica y estadísticamente significativas en la mortalidad y en los eventos cardiovasculares y cerebrovasculares. Adicionalmente, el tratamiento intensivo con estatinas mostró mayor reducción en los eventos cardiovasculares y cerebrovasculares ateroscleróticos al compararlo con el tratamiento de intensidad moderada. No se encontraron diferencias significativas en el riesgo de desarrollar cáncer al comparar estatinas frente a placebo pero sí se encontró un incremento de nueve por ciento en el riesgo de presentar diabetes mellitus asociado al tratamiento con estatinas. Conclusiones: Se formulan recomendaciones a favor del uso de estatinas como primera línea de tratamiento de hipercolesterolemia, y se establecen criterios para definir la intensidad de la terapia (alta o moderada respuesta) según el riesgo cardiovascular a 10 años, el nivel de colesterol LDL (cLDL), la edad y los antecedentes personales y los familiares.

Objective: To evaluate the impact of statin therapy on the incidence and recurrence of cardiovascular and cerebrovascular events (primary and secondary prevention), the levels of lipid fractions and the incidence of side effects (cancer and diabetes mellitus) in people with hypercholesterolemia. Methods: A clinical practice guideline was developed following the guidelines of the methodological guidance of the Ministry of Health and Social Protection to systematically collect the evidence and make recommendations using the GRADE methodology. Results: A beneficial effect of pharmacological treatment with statins in both primary prevention and secondary prevention was evident, achieving clinically and statistically significant reductions in mortality and cardiovascular and cerebrovascular events. Additionally, intensive statin therapy showed greater reduction in atherosclerotic cardiovascular and cerebrovascular events as compared to the treatment of moderate intensity. No significant differences in the risk of developing cancer by comparing statins versus placebo were found, but a 9% increase in the risk of diabetes mellitus associated with statin therapy was found. Conclusions: Recommendations for the use of statins as first-line treatment of hypercholesterolemia are formulated, and criteria to define the intensity of therapy (high or moderate response) as cardiovascular risk at 10 years, level of LDL (LDLc), age and personal and family history were established.

Cuerpos extraños en tracto gastrointestinal asociados a trastorno mental: reporte de caso / Associated mental upheaval to ingestion of strange bodies: case report

Reportamos un caso de mortalidad de un hombre de 49 años con retardo mental asociado a alteración en su comportamiento con actitudes de autoagresión como clavarse agujas e ingesta múltiple de cuerpos extraños, que lo llevó a diversas complicaciones que requieren la participación multidisciplinaria de servicios como psiquiatría, cirugía general, UCI y medicina interna. A la luz de este caso reportado se hace una revisión del tema.

We described the case postmortem of a man of 49 years with associated mental retardation to alteration in its behavior with auto aggression attitudes, being representative case but of the presented/displayed ones in the service of psychiatry, which required multidisciplinary valuation general surgery, internal medicine, unit of intensive care.

Características clínicas y epidemiológicas de la leptospirosis en el departamento del Quindío, 2005-2006 / Clinical and epidemiological characteristics of leptospirosis in the Quindío department (2005-2006)

Objetivo. Describir el comportamiento clínico, epidemiológico y serológico de los pacientes con leptospirosis humana en el departamento del Quindío en un periodo de 2 años (2005-2006). Diseño. Estudio prospectivo de serie de casos. Resultados. Se diagnosticaron 38 casos de leptospirosis humana en el 2005 y 31 casos en el 2006, en el departamento del Quindío. En ellos se encontró una letalidad de 13% en el 2005 y de 3,2% en el 2006. Las manifestaciones clínicas más frecuentes fueron fiebre, mialgia, ictericia y cefalea. La prueba MAT estandarizada fue el método diagnóstico confirmatorio. La variedad serológica icterohemorrágica se encontró con mayor frecuencia y estuvo presente en la mayoría de los casos de mortalidad. Los hallazgos paraclínicos más frecuentes fueron alteraciones de la función hepática (78%) PK elevada (60%). Conclusiones. Contrario a lo que se cree, la leptospirosis sintomática en el departamento del Quindío no se encontró en la población rural sino en la población urbana. Al realizar la búsqueda, el diagnóstico y el tratamiento adecuado, se disminuyeron las complicaciones y la mortalidad, como se puede observar al comparar los años 2005 y 2006.

Objective. To describe the symptoms, clinical laboratory results and outcome of patients with human leptospirosis in department of Quindío, during two years (2005-2006) Methods. Case series Results. 38 cases were confirmed in 2005 and 31 in 2006. Mortality occurred in 12% in 2005 and in 3% of the cases in 2006. The most important symptoms were fever, myalgies and headache. The MAT serological assay was the confirmatory test in all cases.The icterohemorragic serovar was the most frequent and it was found in the majority of the mortal cases. In 75% there was hepatic dysfunction as revealed by laboratory tests and in 70% of patients there was a rise in levels of creatin kynases enzymes. Conclusions. Contrary to common belief, clinical leptospirosis in Quindío was not found in rural but in urban population. Between the two years in Quindío there were improvements in diagnosis and clinical treatment, leading to an important reduction in mortality.